Vinpocetine in the treatment of poststroke cognitive dysfunction

Liu, Yang; Yin, Yanying; Lu, Qiaoli; Dan, Ying; Xu, Meisong; Song, Ge; Li, Chen

doi:10.1097/md.0000000000013685

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers consider this effect of vinpocetine as an analog of ischemic preconditioning, the most powerful form of endogenous tissue protection against ischemia [ 25 ]. In patients with dementia, it has also been found to cause improvement in speech, movement, memory disorders, improvement of the quality of life [ 26 ]. But randomized trials in this regard are not so robust as in the acute stage of cerebral infarction.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Panda

Ramachandran²,

Suthar

2022

Neurocrit Care

View full text Add to dashboard Cite

Background Vinpocetine as a neuroprotective agent is effective in acute ischemic stroke in some randomized controlled trials (RCTs). Since the last systematic review has been published in 2008, which didn’t find conclusive evidence favoring its use, two more RCTs have also been completed. Methods Relevant electronic databases were searched with a suitable combination of Medical Subject Headings terms to detect publications describing RCTs exploring the safety and efficacy of vinpocetine in patients with acute ischemic stroke. The risk of bias was determined by using the Cochrane Collaboration’s tool for assessing the risk of bias in RCTs after full-text review and relevant data extraction. Higgins and Thompson’s I 2 method was used to assess heterogeneity in studies. The presence of publication bias was assessed by Egger’s test. We used a random effect model when I 2 was more than 50% and a fixed-effect model for other parameters. Results Four placebo-controlled RCTs enrolling a total of 601 and 236 patients in vinpocetine and placebo groups, respectively, were included. The number of patients with death or significant disability was lower in the vinpocetine group than that in the placebo group at both 1 and 3 months (relative risk 0.80, 95% confidence interval [CI] 0.65–0.99 and relative risk 0.67, CI 0.48–0.92, p = 0.04 and 0.02, respectively). The degree of disability in participants at 1 month and 3 months was also lower in vinpocetine group than that in the placebo group (standardized mean difference (SMD) 0.49, 95% CI 0.03–0.95 and SMD 1.22, CI 0.23–2.24, p = 0.001 and 0.04, respectively). Change in mini-mental state examination score compared with baseline at trial enrolment was also better in the vinpocetine group than in the placebo group (pooled weighted mean difference 0.92, 95% CI 0.02–1.82, p = 0.04). Conclusions Vinpocetine has some promising efficacy in patients with ischemic stroke when used in the acute stage in reducing the disability, but presently there is not enough evidence to suggest that it also reduces case fatality. More double-blind, placebo-controlled RCTs of adequate sample size are needed before making recommendations for the routine administration of vinpocetine for all patients with acute ischemic stroke. Supplementary Information The online version contains supplementary material available at 10.1007/s12028-022-01499-y.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Panda

Ramachandran²,

Suthar

2022

Neurocrit Care

View full text Add to dashboard Cite

show abstract

“… 32 Recently, the protocol of meta-analysis for treating stroke-related disease has been established to evaluate the efficacy and safety of Vinp. 33 Researchers assumed that it could also be protective in conditions of hypoxia and ischemia. The assumption has been evidenced by multiple clinical studies on patients suffering ischemic stroke.…”

Section: Discussionmentioning

confidence: 99%

Vinpocetine Attenuates Ischemic Stroke Through Inhibiting NLRP3 Inflammasome Expression in Mice

Han

Wang

Wen

et al. 2020

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

Advances in Nanomedicines: A Promising Therapeutic Strategy for Ischemic Cerebral Stroke Treatment

Li,

Xie,

2024

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Ischemic stroke, prevalent among the elderly, necessitates attention to reperfusion injury post treatment. Limited drug access to the brain, owing to the blood–brain barrier, restricts clinical applications. Identifying efficient drug carriers capable of penetrating this barrier is crucial. Blood–brain barrier transporters play a vital role in nutrient transport to the brain. Recently, nanoparticles emerged as drug carriers, enhancing drug permeability via surface-modified ligands. This article introduces the blood–brain barrier structure, elucidates reperfusion injury pathogenesis, compiles ischemic stroke treatment drugs, explores nanomaterials for drug encapsulation and emphasizes their advantages over conventional drugs. Utilizing nanoparticles as drug-delivery systems offers targeting and efficiency benefits absent in traditional drugs. The prospects for nanomedicine in stroke treatment are promising.

show abstract

Vinpocetine in the treatment of poststroke cognitive dysfunction

Cited by 3 publications

References 22 publications

Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Vinpocetine Attenuates Ischemic Stroke Through Inhibiting NLRP3 Inflammasome Expression in Mice

Advances in Nanomedicines: A Promising Therapeutic Strategy for Ischemic Cerebral Stroke Treatment

Contact Info

Product

Resources

About